Search This Blog

Tuesday, December 1, 2020

Hospital Stocks Are Heading Higher. So Are Covid-19 Cases

 Coronavirus hospitalizations have soared to all-time-highs, threatening to strain health-care facilities across the U.S. again. But this time, investors are less concerned.

Shares of several publicly traded hospital systems finished November with their best performances in months, with national hospital operators including Tenet Healthcare Corp. and HCA Healthcare Inc. both jumping at least 21%. That is far better than the S&P 500's 11% monthly gain and the 7.8% rise for the index's health-care sector.

November sent the U.S. stock market on yet another wild ride, driven by a string of positive Covid-19 vaccine results and a quicker-than-expected resolution of the presidential election. Both events helped push major U.S. stock indexes to new records as traders scrambled to scoop up investments that have been beaten-down this year. In addition to hospital stocks, shares of retailers, restaurants, energy stocks and cruise liners also jumped. Elsewhere across financial markets, crude oil, junk bonds and metals such as copper and platinum rallied.

On its face, the recent outperformance of hospital stocks could be perceived as one of the beneficiaries of the latest round of bargain-hunting by investors -- after all, hospital chains such as Tenet and Universal Health Services Inc. are both still trading 11% or more below their respective 2020 highs after plunging during the market rout.

Yet some investors and analysts say they also believe that the recent rally has legs that could extend beyond November, even as rising Covid-19 cases threaten to overrun hospitals again.

"We're bullish," said A.J. Rice, a health-care services analyst at Credit Suisse, which has an "outperform" rating on Tenet, Universal Health and HCA. "Absent a national lockdown again, we think these companies can deliver on expectations and even exceed them. And that should be sufficient to at least relatively outperform the market overall."

Driving the optimism around hospital and health-care facilities, analysts and investors say, is increased clarity about the months ahead. Although two key Senate seats in Georgia won't be decided until the January runoff election, many traders are anticipating that the government will remain divided -- an outcome that reduces the chances of a major health-care overhaul.

And statements from some of the Supreme Court's conservative justices suggest the Affordable Care Act may survive its latest test, a case argued last month by Republican-leaning states seeking to challenge it.

The survival of the Affordable Care Act -- combined with a gridlocked government -- would make it unlikely that health-care policy will substantially change. That in turn, analysts said, will be advantageous for hospitals, which have benefited from greater volumes of insured patients.

"The [election] outcome probably is as good as we could have hoped," said Whit Mayo, managing director of equity research at UBS. "The [chance] of seeing more coverage is probably greater than less coverage. And that's almost always a good thing for everyone in health-care services."

One of the biggest challenges for hospital systems in the months ahead will be the sharp climb in Covid-19 cases, which public-health officials expect will worsen in the coming weeks as more Americans test positive after traveling for Thanksgiving. The U.S. reported more than 135,000 new coronavirus infections Sunday, according to the Covid Tracking Project, and hospitalizations surged to more than 93,000 -- a new record.

The jump in cases threatens to overtax hospital systems again. But this time, investors and analysts expect hospital systems to better weather the Covid-19 influx, thanks to a deeper understanding of how to treat the virus and how to manage hospital capacity. And unlike this spring, when states across the country imposed restrictions on elective procedures, analysts anticipate that local governments will instead leave those decisions to hospital systems.

Already, many hospitals seem more willing to push ahead with the profitable procedures that hospitals routinely conduct, especially after many systems have enjoyed a faster-than-expected rebound in hospital visits for non-coronavirus patients. That -- along with cutting expenses, including via furloughs and reducing salaries at some companies -- has helped turn around hospitals' financial landscape.

Federal assistance earlier this year, including $175 billion in direct aid approved by Congress for health-care providers across the U.S., has also delivered relief.

"I do think investors are becoming comfortable with the fact that hospitals can operate in a Covid environment and that everything doesn't have to go into a complete shutdown," said Frank Morgan, a research analyst at RBC Capital Markets.

Still, even with vaccine optimism, some analysts note that the Covid-19 landscape could shift sharply if outbreaks significantly worsen in the coming weeks. Some nonprofit hospitals have begun putting elective surgeries on pause, and health-care workers are anxious about what could be a sustained influx of patients after already enduring an unrelenting year.

Even so, investor sentiment on hospital companies and the overall health-care sector remains positive. In its latest survey released in November, Bank of America said that health care remains the most overweight sector among fund managers.

Recent options activity, meanwhile, has indicated that investors became increasingly bullish on HCA and Universal Health in November, compared with the month before, said Michael Khouw, chief investment officer of Optimize Advisors. Activity in the options market implies that, on average, traders expect a nearly 7% increase in share price for HCA by mid-March and an almost 12% increase for Universal Health by mid-April, according to his data analysis.

https://www.marketscreener.com/quote/stock/UNIVERSAL-HEALTH-SERVICES-40311163/news/Hospital-Stocks-Are-Heading-Higher-So-Are-Covid-19-Cases-31908086/

Boston Scientific Sells BTG Specialty Pharmaceuticals Unit for $800 M

 Boston Scientific Corp. on Tuesday said it agreed to sell its BTG specialty pharmaceuticals business for $800 million in cash to affiliates of SERB, a European specialty pharmaceutical group backed by private-equity firm Charterhouse Capital Partners.

The Marlborough, Mass., maker of medical devices said the sale, which it expects to complete in the first half of 2021, will result in a pretax loss of about $200 million, which it will book in the fourth quarter.

Boston Scientific said the BTG business makes antidotes used in hospitals and emergency-care settings, including the CroFab, DigiFab and Voraxaze products, which are expected to generate roughly $210 million in revenue this year. The unit has five facilities and about 280 employees around the world.

Boston Scientific, which acquired BTG PLC last year for about $3.7 billion net of cash on hand, said it will have shed two non-medical-device portions of the U.K. interventional medicine company for more than $1 billion in net proceeds.

https://www.marketscreener.com/quote/stock/BOSTON-SCIENTIFIC-CORPORA-11935/news/Boston-Scientific-Sells-BTG-Specialty-Pharmaceuticals-Unit-for-800-Million-31908944/

UnitedHealth guidance for 2021 includes $1.80-per-share hit from COVID-19

 UnitedHealth Group Inc. UNH, -0.47% said Tuesday it now expects full-year revenue of about $257 billion, yielding per-share earnings of about $15.90 and adjusted EPS of $16.75. The FactSet consensus is for EPS of $16.73 and revenue of $256.7 billion. The company offered the updated guidance in a statement ahead of an analyst day. It also set guidance for 2021 for revenue to range from $277 billion to $280 billion and adjusted EPS to range from $17.75 to $18.25. Those numbers include a $1.80 per share hit from continuing COVID-19 effects, such treatment and testing costs, the impact of people deferring care into 2021 and other factors. The FactSet consensus is for EPS of $18.39 and revenue of $278.5 billion. Shares were up 0.5% premarket and have gained 14.4% in the year to date, while the S&P 500 SPX, -0.46% has gained 12% and the Dow Jones Industrial Average DJIA, -0.90% has gained 3.9%.

https://www.marketwatch.com/story/unitedhealth-sets-guidance-for-2021-that-includes-a-180-per-share-hit-from-covid-19-effects-2020-12-01

When and which COVID-19 vaccines are likely to be available in Asia

  Pfizer Inc with partner BioNTech SE, Moderna Inc and AstraZeneca Plc have released trial data this month showing their experimental vaccines are effective in preventing the disease. If regulators approve any of the vaccines in coming weeks, the companies have said distribution could begin almost immediately with governments around the world.

But many Asian countries do not expect to receive big amounts initially, and below are estimated distribution timelines, supply deals announced so far and clinical trials under way in the region.

AUSTRALIA

It has agreed to buy 135 million doses: 34 million from AstraZeneca, 40 million from Novavax Inc, 10 million from Pfizer and 51 million from CSL Ltd.

It expects delivery of 3.8 million doses of AstraZeneca’s vaccine in January and February next year.

CHINA

China has not announced supply deals with Western drugmakers, which instead have partnered with private companies.

AstraZeneca’s vaccine may be approved in China by mid-2021 and its Chinese partner Shenzhen Kangtai Biological Products plans to have annual production capacity of at least 100 million doses of the vaccine by end-2020.

For the Pfizer/BioNTech vaccine, a unit of Shanghai Fosun Pharmaceutical Group plans a Phase 2 trial.

Tibet Rhodiola Pharmaceutical Holding is bringing in Russian vaccine candidate Sputnik V and plans early and mid-stage trials of the shot in China.

China has also approved three vaccine candidates developed by Sinovac and state-owned Sinopharm for emergency use programme, and Sinopharm is hopeful of its two candidates receiving conditional approval for general public use within this year.

JAPAN

Japan has deals to purchase 120 million doses from Pfizer/BioNTech in the first half of next year, 120 million from AstraZeneca, of which first 30 million will be shipped by March 2021, and 250 million from Novavax.

It is also in talks with Johnson & Johnson and has a deal with Shionogi & Co.

Experts said vaccine makers would need to conduct at least Phase 1-2 trials in Japan before seeking approval.

SOUTH KOREA

It aims to secure vaccines for 10 million people from COVAX and 20 million people from separate deals with drugmakers by the end of this year.

It has the “Optional Purchase” arrangement with COVAX that allows it to select vaccines from specific vaccine makers.

The timing of the procurement and the amount depend on the production schedule of those vaccines, according to health officials.

Inoculation is likely to start in the second quarter of next year to allow more time to observe potential side effects.

INDIA

The head of the Serum Institute of India, which makes the AstraZeneca vaccine, said on Nov 23 the positive late-state trial result of the candidate will allow it to seek emergency use authorisation by year-end, before gaining approval for a full rollout by February or March next year.

India also expects a government-backed vaccine to be launched as early as February, while it is conducting a late-stage trial of Sputnik V.

TAIWAN

Taiwan aims to secure around 15 million doses initially, both via the COVAX scheme and by directly purchasing from vaccine makers, and may buy additional 15 million doses.

The government has said it hopes to begin vaccinations in the first quarter of next year.

THE PHILIPPINES

It is in talks with AstraZeneca for the supply of at least 20 million doses, which may arrive in the country in the second quarter of next year. It hopes to lock in 60 million doses in total and also is in talks with Pfizer and Sinovac.

Vaccine makers can apply for approval with the country’s regulators even if no clinical trial is done in the Philippines.

INDONESIA

It is one of the countries listed as 92 low and middle income economies, which means it is entitled to have access to vaccines through COVAX for 20% of its population, or approximately 106-107 million doses if each person gets two injections.

Indonesia is testing Sinovac vaccine and preparing to start mass vaccination for medical staff and other frontline workers as early as late January.

VIETNAM

A government official says vaccines from COVAX would cover only 20% of its population and the country is likely to have a chance to secure separate deals soon as overall demand is very high.

BANGLADESH

Bangladesh signed a deal with India’s Serum to buy 30 million doses of the AstraZeneca vaccine.

It also expects to receive 68 million doses from GAVI at a subsidized rate, a senior health ministry official said.

https://www.reuters.com/article/us-health-coronavirus-vaccines-asia-fact/factbox-when-and-which-covid-19-vaccines-are-likely-to-be-available-in-asia-idUSKBN28B3QD

UK not planning vaccine passports for pubs, theatre, sports events

 Senior British minister Michael Gove said that the government was not planning a system of vaccine passports which would prevent those who hadn’t had a COVID-19 jab from going to the pub or attending events.

“I certainly am not planning to introduce any vaccine passports and I don’t know anyone else in government (who is),” Gove told Sky News on Tuesday.

The minister in charge of vaccines, Nadhim Zadhawi, said on Monday that he expected people who refused the COVID-19 vaccine could find that they were refused entry to restaurants, bars, cinemas and sports venues.

When asked about that, Gove said he did not think people would need a vaccine passport to go to the pub, the theatre or to sports events.

“The most important thing to do is to make sure we vaccinate as many people as possible,” he said.

https://www.reuters.com/article/us-health-coronavirus-britain/uk-not-planning-vaccine-passports-for-pubs-theatre-sports-events-idUSKBN28B42W

European agency to decide on Pfizer's vaccine by Dec. 29, Moderna's by Jan. 12

  The European Medicines Agency said on Tuesday that if its experts have received enough data from drugmakers Pfizer and Moderna about their candidate vaccines against the coronavirus, the agency would complete its reviews by Dec. 29 and Jan. 12, respectively, at latest.

The companies said earlier on Tuesday that they had submitted approval requests for their vaccine candidates to the European drugs regulator.

https://www.reuters.com/article/us-health-coronavirus-vaccines-europe/european-agency-to-decide-on-pfizers-vaccine-by-dec-29-modernas-by-jan-12-idUSKBN28B4P6

AstraZeneca sells former blockbuster cholesterol drug for $320 m

 AstraZeneca said on Tuesday it would sell rights to its erstwhile blockbuster cholesterol drug, Crestor, to German pharmaceutical company Gruenenthal GmbH for an upfront payment of $320 million as the British drugmaker focuses on its cancer treatments portfolio.

Crestor, which brought in revenue of over $5 billion for AstraZeneca in 2015, was among its best-selling medicines and used to contribute to around 20% of the company’s total revenue.

Crestor was hit by the arrival of cheap generic rivals in 2016 and newer medicines such as Tagrisso and Imfinzi for cancer and Fasenra for severe asthma were touted by AstraZeneca as medicines that would take over.

AstraZeneca, which is among the front-runners in the race to develop a vaccine for the novel coronavirus, has been trying to focus on its cancer drugs as it streamlines its business.

The London-listed company has been viewed as having a head start in the race for cancer treatments and sales of those medicines, including blockbuster lung cancer treatment Imfinzi, have been key to its turnaround.

Tuesday’s deal will give Gruenenthal rights to sell Crestor and associated medicines in more than 30 countries in Europe, except the UK and Spain, AstraZeneca said.

AstraZeneca will continue to manufacture and supply the drug to GrĂ¼nenthal during a transition period and will continue to sell it in other regions, including North America and China, it said.

The deal is expected to close in the first quarter of 2021, AstraZeneca said, adding that GrĂ¼nenthal could make milestone payments of up to $30 million.

In October, AstraZeneca said it would sell rights for its heart failure and blood pressure medicines Atacand and Atacand Plus to Germany’s Cheplapharm Arzneimittel GmbH for $400 million.

The British drugmaker said that the divestment of Crestor will not affect its financial guidance for 2020.

https://www.reuters.com/article/us-astrazeneca-divestiture/astrazeneca-sells-former-blockbuster-cholesterol-drug-for-320-million-idUSKBN28B3Z5